Scroll

brexpiprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychotropics, phenylpiperazine derivatives	5014	913611-97-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: brexpiprazole rexulti OPC-34712 OPC 34712	an atypical antipsychotic the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors Molecular weight: 433.57 Formula: C25H27N3O2S CLOGP: 4.90 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 44.81 ALOGS: -5.28 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

brexpiprazole
rexulti
OPC-34712
OPC 34712

an atypical antipsychotic the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors

Molecular weight: 433.57
Formula: C25H27N3O2S
CLOGP: 4.90
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 44.81
ALOGS: -5.28
ROTB: 7

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.46 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.34 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	54.37 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
July 27, 2018	EMA	OTSUKA PHARM CO LTD
Jan. 19, 2018	PMDA	Otsuka Pharmaceutical Co., Ltd.
July 10, 2015	FDA	OTSUKA PHARM CO LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	414.69	26.22	106	4778	8123	50592117
Weight increased	300.51	26.22	205	4679	201686	50398554
Schizoaffective disorder	262.17	26.22	57	4827	2149	50598091
Off label use	171.07	26.22	218	4666	474208	50126032
Drug level increased	140.27	26.22	57	4827	19211	50581029
Tardive dyskinesia	138.94	26.22	44	4840	7235	50593005
Restlessness	113.07	26.22	53	4831	25120	50575120
Electrocardiogram QT prolonged	104.43	26.22	64	4820	51822	50548418
Product use in unapproved indication	97.14	26.22	84	4800	115735	50484505
Suicidal ideation	88.32	26.22	59	4825	55326	50544914
Mania	81.82	26.22	33	4851	10883	50589357
Inability to afford medication	78.36	26.22	20	4864	1510	50598730
Product administered to patient of inappropriate age	76.47	26.22	22	4862	2608	50597632
Tremor	66.74	26.22	68	4816	114835	50485405
Sinus rhythm	56.62	26.22	13	4871	627	50599613
Drug interaction	47.90	26.22	76	4808	199545	50400695
Extrapyramidal disorder	47.37	26.22	23	4861	11747	50588493
Anger	45.17	26.22	22	4862	11311	50588929
Hallucination, auditory	43.28	26.22	21	4863	10707	50589533
Anxiety	43.11	26.22	68	4816	177538	50422702
Eye movement disorder	38.44	26.22	15	4869	4530	50595710
Depression	38.30	26.22	62	4822	165361	50434879
Wrong technique in product usage process	38.04	26.22	36	4848	55474	50544766
Food craving	37.24	26.22	11	4873	1428	50598812
Collagen-vascular disease	33.65	26.22	6	4878	78	50600162
Oculogyric crisis	32.93	26.22	10	4874	1427	50598813
Insomnia	31.90	26.22	59	4825	174806	50425434
Psychiatric symptom	31.44	26.22	13	4871	4557	50595683
Sedation	31.40	26.22	25	4859	30585	50569655
Adverse event	31.16	26.22	29	4855	43734	50556506
Feeling abnormal	30.34	26.22	48	4836	125444	50474796
Increased appetite	29.67	26.22	15	4869	8346	50591894
Incorrect dose administered	26.86	26.22	28	4856	48386	50551854
Parakeratosis	26.73	26.22	6	4878	261	50599979

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	251.60	35.25	64	2009	6678	29565776
Weight increased	118.69	35.25	71	2002	76596	29495858
Off label use	76.70	35.25	99	1974	300701	29271753
Product administered to patient of inappropriate age	73.83	35.25	20	2053	2635	29569819
Tardive dyskinesia	72.57	35.25	23	2050	5235	29567219
Restlessness	60.59	35.25	30	2043	22115	29550339
Anxiety	54.20	35.25	46	2027	85319	29487135
Suicidal ideation	53.09	35.25	32	2041	34684	29537770
Inability to afford medication	49.91	35.25	12	2061	980	29571474
Apathy	49.62	35.25	18	2055	6153	29566301
Psychotic disorder	45.30	35.25	24	2049	20330	29552124
Loss of libido	44.29	35.25	13	2060	2283	29570171
No adverse event	42.87	35.25	22	2051	17456	29554998
Product use in unapproved indication	39.78	35.25	39	2034	86836	29485618
Anger	36.58	35.25	17	2056	10873	29561581
Orthostatic hypertension	35.85	35.25	7	2066	213	29572241

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	183.12	28.80	55	4087	11455	64483135
Weight increased	155.49	28.80	120	4022	213228	64281362
Product use in unapproved indication	121.26	28.80	96	4046	176522	64318068
Tardive dyskinesia	116.91	28.80	37	4105	9141	64485449
Product administered to patient of inappropriate age	109.01	28.80	30	4112	4571	64490019
Off label use	105.90	28.80	163	3979	632643	63861947
Restlessness	95.60	28.80	48	4094	39737	64454853
Suicidal ideation	82.49	28.80	52	4090	66490	64428100
Hallucination, auditory	70.70	28.80	30	4112	16909	64477681
Anxiety	62.89	28.80	71	4071	202578	64292012
Inability to afford medication	62.29	28.80	16	4126	1870	64492720
Tremor	60.29	28.80	60	4082	148170	64346420
Apathy	50.57	28.80	21	4121	11211	64483379
Loss of libido	44.81	28.80	13	4129	2391	64492199
Oculogyric crisis	44.11	28.80	13	4129	2525	64492065
Anger	40.75	28.80	20	4122	15721	64478869
Psychotic disorder	37.81	28.80	25	4117	34553	64460037
Collagen-vascular disease	36.94	28.80	6	4136	67	64494523
Suicide attempt	35.00	28.80	32	4110	70975	64423615
Neuroleptic malignant syndrome	34.65	28.80	21	4121	24975	64469615
No adverse event	34.54	28.80	22	4120	28539	64466051
Dissociation	33.66	28.80	11	4131	3000	64491590
Psychiatric symptom	32.59	28.80	13	4129	6260	64488330
Depression	31.40	28.80	48	4094	183243	64311347
Insomnia	31.38	28.80	50	4092	197786	64296804

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AX16	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Other antipsychotics
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018491	Dopamine Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
FDA EPC	N0000175430	Atypical Antipsychotic

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Schizophrenia	indication	58214004	DOID:5419
Major depressive disorder	indication	370143000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.14	acidic
pKa2	8.07	Basic
pKa3	0.9	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8349840	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	8618109	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	9839637	April 12, 2026	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.25MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
0.5MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
1MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
2MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
3MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION
4MG	REXULTI	OTSUKA	N205422	July 10, 2015	RX	TABLET	ORAL	Dec. 27, 2024	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9.52	SCIENTIFIC LITERATURE	DRUG LABEL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	9.92	SCIENTIFIC LITERATURE	DRUG LABEL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	9.33	SCIENTIFIC LITERATURE	DRUG LABEL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	7.23	SCIENTIFIC LITERATURE
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	7.17	SCIENTIFIC LITERATURE
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	6.80	SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.82	SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	IC50	7.54	SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	IC50	6.86	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	ANTAGONIST	Ki	8.72	SCIENTIFIC LITERATURE
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.77	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.24	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	8.43	SCIENTIFIC LITERATURE
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.42	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	7.50	SCIENTIFIC LITERATURE
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	ANTAGONIST	Ki	9.23	SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	IC50	6.03	SCIENTIFIC LITERATURE
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	8.20	SCIENTIFIC LITERATURE
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.59	SCIENTIFIC LITERATURE
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	9.77	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.85	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.47	SCIENTIFIC LITERATURE
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	8.96	SCIENTIFIC LITERATURE
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	7.72	SCIENTIFIC LITERATURE
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	9.70	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	10.05	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	8.64	CHEMBL

External reference:

ID	Source
D10309	KEGG_DRUG
4034625	VUID
N0000191737	NUI
4034625	VANDF
CHEBI:134716	CHEBI
CHEMBL2105760	ChEMBL_ID
C000591922	MESH_SUPPLEMENTAL_RECORD_UI
7672	IUPHAR_LIGAND_ID
9552	INN_ID
DB09128	DRUGBANK_ID
2J3YBM1K8C	UNII
11978813	PUBCHEM_CID
1658314	RXNORM
234913	MMSL
31120	MMSL
d08373	MMSL
716069007	SNOMEDCT_US
781292006	SNOMEDCT_US
C3885614	UMLSCUI
016270	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-035	TABLET	0.25 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-036	TABLET	0.50 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-037	TABLET	1 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-038	TABLET	2 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-039	TABLET	3 mg	ORAL	NDA	37 sections
Rexulti	HUMAN PRESCRIPTION DRUG LABEL	1	59148-040	TABLET	4 mg	ORAL	NDA	37 sections